SYMBICORT® GAINS EUROPEAN UNION MUTUAL RECOGNITION APPROVAL FOR ASTHMA CONTROL
AstraZeneca announced today that Symbicort®, a new and innovative treatment for asthma, has been granted approval through the Mutual Recognition Procedure (MRP) in 14 European Union (EU) states plus Norway and Iceland. This follows initial approval of Symbicort® in Sweden in August 2000. Sweden acted as the reference member state for the MRP application. In addition to these approvals, Symbicort® has been approved in Switzerland, and applications have been submitted in both Canada and Australia.
Other news from the department research and development

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New products from Clariant
Orciprenaline
Rudolf_Magnus
Metoclopramide

Synthetic diamond steps closer to next generation of high performance electrochemical applications - Element Six and the University of Warwick partnership explores electrochemical properties of boron-doped synthetic diamond electrodes
